@article {Patalano333, author = {Francesco Patalano and Donald Banerji and Peter D{\textquoteright}Andrea and Robert Fogel and Pablo Altman and Paul Colthorpe}, title = {Addressing unmet needs in the treatment of COPD}, volume = {23}, number = {133}, pages = {333--344}, year = {2014}, doi = {10.1183/09059180.00004014}, publisher = {European Respiratory Society}, abstract = {The burden of chronic obstructive pulmonary disease (COPD) is considerable, both socially and economically. Central to COPD management is the use of long-acting bronchodilators, which provide patients with optimal bronchodilation and improvements in symptoms. The once-daily, long-acting β2-agonist indacaterol, the long-acting muscarinic antagonist glycopyrronium, and the indacaterol/glycopyrronium fixed-dose combination QVA149 have all been shown to significantly improve lung function and patient-reported outcomes. The ability to take medication appropriately is important. Easy to use, low resistance devices may help patients take their medication and achieve good drug deposition. There is a need to optimise COPD management by treating the right patients with the right therapy at the right time during the course of their disease. Herein, we present a view on the current COPD management landscape and current unmet needs, and look to the future of COPD treatment and how patient care can be optimised.}, issn = {0905-9180}, URL = {https://err.ersjournals.com/content/23/133/333}, eprint = {https://err.ersjournals.com/content/23/133/333.full.pdf}, journal = {European Respiratory Review} }